Free Content Targeted Fc2′-3-PE40 chimeric protein abolishes passive cutaneous anaphylaxis in mice

Authors: Fishman, A.1; Prus, D.2; Belostotsky, R.1; Lorberboum-Galski, H.1

Source: Clinical & Experimental Immunology, Volume 119, Number 3, March 2000 , pp. 398-403(6)

Publisher: Blackwell Publishing

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

The alarming increase in the incidence of allergic diseases in the past decade has led to a clear call for more effective treatment. Recently, we reported on the construction of a chimeric protein for targeted elimination of cells expressing FcεRI receptors. This chimeric protein, designated Fc2′-3-PE40, is composed of a Fc fragment of mouse IgE attached to a truncated form of Pseudomonas exotoxin. The Fc2′-3-PE40 chimeric protein was found to be highly cytotoxic to mouse mast cell lines and primary mouse mast cells. We now demonstrate that Fc2′-3-PE40 successfully prevents the development of passive cutaneous anaphylaxis reaction (PCA) in mice. Treatment with Fc2′-3-PE40 for 7 days prevented the PCA reaction in mice by 80% compared with that in control mice given only PBS. Fc2′-3-PE40M, the mutated, enzymatically inactive analogue of Fc2′-3-PE40, did not display this activity. Fc2′-3-PE40 was also effective when given as a single dose 16 h before antigen exposure, resulting in complete inhibition of the PCA reaction. Moreover, treatment with Fc2′-3-PE40 did not cause mast cell degranulation, as the serum histamine values of mice treated with Fc2′-3-PE40 were within the range obtained for control, untreated mice. Thus, the Fc2′-3-PE40 chimeric protein offers a novel approach to the treatment of allergic disorders.

Keywords: mast cells; basophils; allergy; cytotoxicity; Fc receptors; in vivo animal models

Document Type: Research article

DOI: 10.1046/j.1365-2249.2000.01151.x

Affiliations: 1: Department of Cellular Biochemistry, Hebrew University-Hadassah Medical School, and 2: Department of Pathology, Hadassah University Hospital, Jerusalem, Israel

You have access to the full text article on a website external to Ingentaconnect.

Please click here to view this article on InterScience.

You may be required to register and activate access on InterScience before you can obtain the full text. If you have any queries please contact onlinehelp@oxon.blackwellpublishing.com

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A